tapebrief
TMO · Q2 2025

TMO · Q3 2025 Earnings

Cautious

Thermo Fisher Scientific

Reported October 22, 2025

30-second summary

Revenue grew 5% to $11.12B with organic growth of 3% — exactly the inflection management implied last quarter — and adjusted EPS of $5.79 came in $0.30 ahead of the prior internal Q3 guide midpoint. FY2025 revenue guidance was raised to $44.1–$44.5B (midpoint up $0.4B) and adjusted EPS to $22.60–$22.86 (midpoint up $0.20), but the underlying organic growth midpoint stayed pinned at 2%, and Analytical Instruments still grew only 4.7%. The print clears the near-term bar; the 2026–2027 3–6% bridge remains an article of faith, not evidence.

Headline numbers

EPS

Q3 FY2025

$5.79

Revenue

Q3 FY2025

$11.12B

+5.0% YoY

Gross margin

Q3 FY2025

41.8%

Free cash flow

Q3 FY2025

$1.84B

Operating margin

Q3 FY2025

17.4%

Key financials

Q3 FY2025
MetricQ3 FY2025YoYQ2 FY2025QoQ
Revenue$11.12B+5.0%$10.86B+2.5%
EPS$5.79—$5.36+8.0%
Gross margin41.8%—41.2%+60bps
Operating margin17.4%—16.9%+50bps
Free cash flow$1.84B—$1.10B+66.5%

Guidance

Company raised FY2025 revenue and adjusted EPS guidance while reaffirming organic growth outlook; Q3 delivered ahead of prior-quarter expectations with strong operating margin expansion and 3% organic growth.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

New guidance

MetricPeriodGuideYoY
Net Interest ExpenseFY 2025approximately $440 million—
Adjusted Tax RateFY 202510.5%—
Net Capital ExpendituresFY 2025$1.4 to $1.7 billion—
Free Cash FlowFY 2025around $7 billion—
Average Diluted Share CountFY 2025approximately 378 million shares—

Changes to prior guidance

MetricPeriodPrior guideNew guideΔResult
Revenue
FY 2025
$43.6 to $44.2 billion$44.1 to $44.5 billion+$0.5B at both low and high endRaised
Adjusted EPS
FY 2025
$22.22 to $22.84$22.60 to $22.86+$0.38 at low end, +$0.02 at high endRaised
Adjusted Operating Margin
FY 2025
22.5% to 22.7%22.7% to 22.8%+0.2 points at low end, +0.1 points at high endRaised

Reaffirmed unchanged this quarter: Organic Revenue Growth (2% at midpoint)

Segment KPIs

Q3 FY2025
SegmentQ3 FY2025YoY
Life Sciences Solutions$2.588B+8.4%
Analytical Instruments$1.893B+4.7%
Specialty Diagnostics$1.174B+4.0%
Laboratory Products and Biopharma Services$5.97B+4.0%

Other KPIs

Q3 FY2025
SegmentQ3 FY2025
Adjusted Operating Margin23.3%
Organic Revenue Growth3%
Life Sciences Solutions Segment Margin37.4%
Specialty Diagnostics Segment Margin27.4%

Management tone

Q4-2024 cost-out push → Q1 macro defensiveness → Q2 explicit 2026–2027 valley framework → Q3 execution-driven raise.

Last quarter the guide raise was funded by $300M of incremental cost actions and US-China tariff relief — discretionary cost control compensating for stuck topline. This quarter the raise is sourced from operational beats: management quantified $0.30 of Q3 adjusted EPS above the midpoint of the prior internal guide, attributing it to "very strong operational performance." That is a meaningfully different posture: Q2 was margin-engineered to a number, Q3 outperformed the number. The 100bps of YoY operating margin expansion to 23.3% — booked while absorbing tariffs and FX — supports the framing.

The AI narrative escalated from peripheral to structural. In prior quarters AI was a product-feature discussion; this quarter management disclosed embedding "OpenAI advanced technology into critical areas of our business, including product development, service delivery, customer engagement, and operations" and rolled out ChatGPT Enterprise company-wide. This is no longer an exploration item — it is being positioned as a productivity lever inside the PPI system, which is the engine of the margin algorithm.

The reshoring story sharpened from generic "trusted partner" framing into specific timing and specific assets. Greenfield sites are now dated to 2027–2028, with faster opportunities in existing-facility expansions. The Sanofi sterile fill-finish site was repositioned from "deal closing" (Q2 framing) to "production node" with $75M of existing business. Importantly, in Q&A Casper repeated that onshoring is one-time incremental equipment and qualification demand, not a structural lift to ongoing consumables — a measured rebuttal to the bull case that reshoring is a multi-year compounding tailwind.

The hedging language is more specific, not softer. Pandemic runoff was quantified at ~1 point of FY headwind. Tariffs are described as "embedded in guidance" at current rates. China decline is explicitly mid-to-high single digits FY. The 3–6% 2026–2027 organic framework was reaffirmed and bridged to the current run rate ("currently at ~3% when adjusting for COVID runoff"). This is management showing its math rather than asking for benefit of the doubt — a posture upgrade vs. Q2.

Recurring themes management leaned on this quarter:

Active management delivering earnings beatsMargin expansion via PPI productivity despite tariffs and FX headwindsAI integration into products and operations (OpenAI partnership)Trusted partner status strengthening customer relationshipsStrategic M&A in bioprocessing and pharma servicesInnovation pipeline in NGS, proteomics, and analytical instruments

Risks management surfaced:

Tariffs and related FX volatility impacting marginsChina market weakness in diagnosticsAcademic and government market softer conditions (low single digit decline)Pandemic revenue runoff headwind (1% impact quantified in LP&BS)Unfavorable mix offsetting productivity gains in multiple segments

Q&A highlights

Michael Riskin · Bank of America

How have customer conversations evolved regarding pharma tariffs, MFN concerns, and reshoring? How will Thermo Fisher benefit from reshoring through facility buildout, Patheon, and fill-finish capacity in the US?

Pharma customers show quiet confidence in navigating government policies. Reshoring activity is accelerating, with greenfield sites coming in 2027-2028. Thermo Fisher is helping customers via pharma services network to move volume to the US, leveraging leadership in sterile fill-finish and the recent Sanofi site acquisition as a production node.

Greenfield sites expected 27-28 timeframeExpansions in existing facilities could occur fasterAcquired Sanofi fill-finish site in USIndustry-leading sterile fill-finish capabilities

Tycho Peterson · Jefferies

Which analytical instrument segments drove outperformance? How is momentum progressing into year-end? Any thoughts on budget flush in 2026?

Mass spectrometry, cryo-electron microscopy, and chromatography were primary drivers of single-digit growth. Strong innovation adoption despite funding environment variability. Chemical analysis remains under pressure. Q4 will have tougher comparisons. Underlying business health is strong.

Single-digit growth delivered in Q3Mass spec, cryo-EM, chromatography were key driversChemical analysis still pressuredHigh single-digit growth comparison in Q4 2024

Jack Meehan · Nefron Research

Is Thermo Fisher tracking to its 3-6% organic growth guidance for 2026? What has changed in confidence levels? What are the modeling implications of recent M&A (filtration/separation and Sanofi site)?

Confidence in 3-6% organic growth unchanged. Company currently at ~3% when adjusting for COVID runoff headwinds. Filtration/separation business expected $750M full-year 2025 revenue, growing at or above company average. First 12 months dilutive by $0.06; improves to mid-teens margins post-integration. Sanofi site has $75M existing business; $0.05 dilution in first 12 months, builds revenue and profitability in 2027. FX tailwind of couple hundred million dollars expected.

3-6% organic growth guidance intactCurrent run rate ~3% (2% reported + ~1% COVID runoff)Filtration/separation: ~$750M 2025 full-year revenueFiltration/separation: $0.06 dilution first 12 months, improving to mid-teens margins

Dan Arias · Stifel

Is small/emerging biotech spending improving? How are pricing dynamics in China evolving on research and industrial side? Are there risks to pricing stability into end of 2026?

Biotech quarter was strong with momentum in clinical research and pharma services. M&A activity by large pharma acquiring biotech helps ecosystem reinvestment cycle. China full-year expected down mid to high single digits, improved from Q2. Pricing dynamics in industrial/pharma are less government-affected than diagnostics, more manageable from private/state-backed enterprises.

Strong biotech quarter with clinical research momentumPharma M&A activity driving positive biotech ecosystem effectsChina full-year expected mid-to-high single digit declineMid single digit decline in Q3 China (vs Q2), improvement from April trade disruptions

Dan Brennan · T. Day Cohen

How should we model onshoring impact on capex and consumables? Is onshoring truly incremental demand or just geographic shift? What's the magnitude of equipment uptake opportunity in 2026? What was the actual tariff impact in Q3 and Q4 expectations?

Onshoring represents real one-time incremental demand (equipment, inventory, qualification runs) but doesn't increase ongoing consumables demand since drug volumes remain constant. Thermo Fisher has stronger presence in new facilities than existing install base due to stronger capabilities/products. Tariff impact was 11 cents favorable in Q3; Q4 tariff assumptions expected to hold given recent increases, no significant pickup expected. Bioproduction experiencing very strong growth, outpacing competitors.

Onshoring is one-time incremental demand, not ongoing consumables growthStronger market share position in new vs existing facilities11 cents tariff and related trade environment benefit in Q3Q4 tariffs expected to hold with no significant pickup

Answers to last quarter's watch list

Did Q3 organic growth deliver the implied ~3%? Yes — reported organic growth was 3%, at the upper end of the FY 1–3% range. Combined with the Q4 tougher comparison and management's reiteration of 2% FY midpoint, this is a clean hit but not a beat. Status: Resolved positively
Is the $300M cost program repeatable or one-time? Q3 commentary did not introduce a fresh incremental cost program, and the operating margin raise (to 22.7–22.8%) was sourced from operating leverage and PPI productivity rather than newly-announced cuts. This implies the Q2 $300M was largely a one-time step-up, not a recurring cadence. Status: Resolved positively
China trajectory — does the high-single-digit decline flatten? Q3 China declined mid-single-digits, an improvement from Q2's high-single-digit decline, and full-year expectation is mid-to-high single digit decline. The trajectory is stabilizing, not deteriorating, but it is still not flat — the assumption underpinning the 2026–2027 bridge remains intact but unproven. Status: Continue monitoring
Analytical Instruments — does -3% inflect? Yes, dramatically: +4.7% YoY in Q3 vs. -3% in Q2, driven by mass spec, cryo-EM, and chromatography. Management flagged tougher Q4 comparisons, so sustainability is the open question. Status: Resolved positively
Sanofi CDMO closure and reshoring signals. Sanofi site is now operationally referenced as a US production node with $75M existing business and a quantified $0.05 first-year EPS dilution. Reshoring narrative sharpened with 2027–2028 greenfield timing. Closure status was not explicitly called out but management speaks of the site in present tense. Status: Resolved positively
Adjusted operating margin progression toward the raised FY range. Q3 hit 23.3%, 100bps YoY and above the raised FY 22.7–22.8% range, with the FY guide itself raised. Margin algorithm is delivering. Status: Resolved positively

What to watch into next quarter

Whether Q4 organic growth holds at or above 2% against the explicit "tougher comparison" warning — particularly in Analytical Instruments, which lapped a high-single-digit growth quarter in Q4-2024 and is the most volatile segment.

Whether the $0.11 Q3 tariff benefit reverses or normalizes in Q4 — management explicitly does not expect comparable Q4 tailwind, so the implied Q4 margin needs to hold on operating leverage alone.

Initial 2026 guidance commentary on the Q4 call: whether the 3–6% organic framework gets dollar-quantified or stays as a band, and whether the dilution from filtration/separation ($0.06) and Sanofi ($0.05) is layered cleanly into the FY2026 build.

China Q4 trajectory — Q3 improved to mid-single-digit decline; sustaining or further narrowing that gap is required for the 2026 bridge. Any return toward high-single-digit decline breaks the assumption.

Bioproduction bookings-to-revenue conversion: management said bookings are outpacing revenue. Q4 will show whether this translates into a step-up in Life Sciences Solutions growth above the +8.4% Q3 print.

FCF tracking against the new ~$7B FY guide: through three quarters TMO needs roughly $2.5B+ in Q4 to make the number — a high bar versus Q3's $1.84B.

Sources

  1. Thermo Fisher Q3 2025 Earnings 8-K Exhibit 99.1 — https://www.sec.gov/Archives/edgar/data/97745/000009774525000150/q32025earnings8kex99_1.htm
  2. Thermo Fisher Q3 2025 earnings call (Mark Casper, Stephen Williamson, and analyst Q&A)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.